Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Integrates MetaCore, MetaDrug With Spotfire's DecisionSuite for Drug Discovery

NEW YORK (GenomeWeb News) — GeneGo and Spotfire have integrated their software products for genomics, proteomics, and gene-expression analysis involved in drug development, GeneGo said today.
GeneGo’s MetaCore 4.2 is a biomarker-identification and -validation tool, and its MetaDrug platform is used to predict metabolism, toxicity, and the effects of small molecule compounds. Spotfire’s DecisionSuite, meantime, visualizes genomics data.  
GeneGo said that using the integrated products will allow researchers to use DecisionSuite to analyze genomics and proteomics data and then use GeneGo’s software to perform pathway and network analysis.
Financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.